Panitumumab
Amgen
['rectal', 'biomarker', 'colorectal']
in a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-egfr antibodies in patients with #colorectalcancer #biomarker #liquidbiopsy #aacr23 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.